Treatment Selection in Recurrent Hodgkin Lymphoma: Balancing Efficacy and Toxicity

The management of recurrent classical Hodgkin lymphoma (cHL) has evolved substantially with the integration of checkpoint inhibitors, antibody-drug conjugates, and novel cellular therapies. In this session, Dr. Alison Moskowitz will examine contemporary treatment-selection strategies that balance efficacy, toxicity, and long-term outcomes across diverse relapse settings. Key topics include the use of PD-1–based salvage regimens, optimization of transplant eligibility and consolidation approaches, management of treatment-related toxicities, and therapeutic options for patients with disease refractory to brentuximab vedotin and checkpoint blockade. Emphasis will be placed on individualized sequencing strategies and evidence-based decision-making to improve outcomes while minimizing treatment burden.